Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Biogen Idec
Femme et Homme Max 99 ans
Biogen Idec Research Limited
MAJ Il y a 4 ans
Daclizumab HYP Extension Study for Subjects with Multiple Sclerosis Who Have Completed 205MS301
The primary objective of the study is to assess the safety and tolerability of long-term treatment with DAC HYP monotherapy in subjects who completed Study 205MS301, Study 205MS203, or Study 205MS302
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Biogen Idec Ltd
MAJ Il y a 4 ans
A Multicenter, Open-Label, Immunogenicity and Safety Study of Avonex® (Interferon Beta-1a) 30 mcg Administered Subcutaneously to Subjects With Relapsing Multiple Sclerosis
To evaluate the immunogenicity of Avonex® 30 mcg when administered SC to interferon-naïve subjects with relapsing MS. The number and percentage of subjects who develop neutralizing antibodies (NAbs) ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Biogen Idec Ltd
MAJ Il y a 4 ans
A Randomized, Open-Label, Multicenter, Phase 2/3 Study to Evaluate the Safety and Efficacy of Lumiliximab in Combination with Fludarabine, Cyclophosphamide, and Rituximab Versus Fludarabine, Cyclophosphamide, and Rituximab Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia
To determine the effectiveness of lumiliximab when used in combination with Fludarabine, Cyclophosfamide and Rituximab (FCR) compared with Fludarabine, Cyclophosphamide and Rituximab (FCR) alone for t...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Homme Max 99 ans
Biogen Idec Hemophilia Inc
MAJ Il y a 4 ans
A clinical study involving people with severe haemophilia A to look at how safe an experimental replacement factor VIII protein (known as rFVIIIFc) is to take and how well it works to prevent and stop bleeds
• To evaluate the safety and tolerability of rFVIIIFc administered as a prophylaxis, weekly, on-demand, and surgical treatment regimen • To evaluate the efficacy of the rFVIIIFc tailored prophylaxis ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Biogen Idec Ltd
MAJ Il y a 4 ans
TYSABRI Long Term Re-Dosing Study
Initial Treatment Period: To further evaluate the safety of natalizumab monotherapy by: 1) evaluating the risk of hypersensitivity and immunogenicity following re-exposure to natalizumab and 2) co...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Biogen Idec Ltd
MAJ Il y a 4 ans
Estudio aleatorizado de interrrupción de tratamiento con Natalizumab" "Randomized Treatment Interruption of Natalizumab
1.Cómo evoluciona la recuperación de la función inmunitaria, utilizando los marcadores indirectos 2. Cómo evoluciona la reaparición de pruebas radiológicas y/o clínicas de actividad de la EM 3. El ef...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Homme Max 99 ans
Biogen Idec Research Ltd
MAJ Il y a 4 ans
A clinical study involving people with severe haemophilia A to look at how two different strengths of an experimental replacement factor VIII protein (known as rFVIIIFc) are processed by the body and how safe it is to take
The primary objective of the study is to characterize the PK of rFVIIIFc administered at vial strengths of 1000 and 3000 IU in subjects with severe hemophilia A.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme
Entre 18 ans
et 99 ans
Biogen Idec
MAJ Il y a 4 ans
BIOGEN IDEC 114-NH-301 : Essai de phase 3 randomisé, en double aveugle, comparant l’efficacité du rituximab associé ou non à du galiximab, chez des patients ayant un lymphome folliculaire. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions]
A phase III, randomized, double-blind study of galiximab in combination with rituximab compared with rituximab in combination with placebo for the treatment of subjects with relapsed or refractory, fo...
Pays
France
Organes
Lymphomes non hodgkinien
Spécialités
Thérapies Ciblées
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Biogen Idec Research Limited
MAJ Il y a 4 ans
Extension Study of BG00012 in Pediatric Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)
The primary objective of the study is to evaluate the long-term safety of BG00012 in subjects who completed Study 109MS202 (NCT02410200).
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Biogen Idec
MAJ Il y a 4 ans
A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Tolerability of Oral Tonapofylline in Patients with Heart Failure and Renal Insufficiency
The primary objective of this study is to assess the safety and tolerability of Tonapofylline administered to subjects with heart failure and renal insufficiency
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Précédent
1
2
3
4
5
6
7
8
9
Suivant